Definium Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912" ], "revenue_estimate": [ null, 44.77, 223.78, 406.99 ], "ebit_estimate": [ -196.65, -178.68, -36.14, 33.3 ], "ebitda_estimate": [ -187.4, -172.3, -56.75, 46.45 ], "net_income_estimate": [ -193.43, -175.61, -40.69, 192.05 ], "per_share_eps_estimate": [ -1.74, -1.53, -0.27, 3.15 ], "eps_nri_estimate": [ -1.75, -1.58, -0.4, 1.54 ], "dividend_estimate": [ null, null, null, null ], "book_value_per_share_estimate": [ 3.08, 2.28, 2.3, 0.74 ], "pretax_income_estimate": [ -192.43, -172.01, -28.1, 230.46 ], "operating_cash_flow_per_share_estimate": [ -1.68, -1.35, -0.85, -1.34 ], "roa_estimate": [ null, null, null, null ], "roe_estimate": [ -61.4, -61.2, -37.8, -113 ], "gross_margin_estimate": [ null, 56.67, 90.2, 88.33 ], "operating_cash_flow_estimate": [ -182.77, -146.87, -92.47, -145.78 ], "pettm_estimate": [ 0, 0, 0, 14.93 ], "long_term_growth_rate_mean": 36.91, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 46.46, "future_eps_nri_estimate_growth": 36.91, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 38.64, "future_ebitda_estimate_growth": 29.66, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 37, "future_pretax_income_estimate_growth": 43.71, "future_book_value_per_share_estimate_growth": -13.42, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 14.66, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 17.04 }

{ "date": [ "202606", "202609", "202612" ], "revenue_estimate": [ null, null, null ], "ebit_estimate": [ -49.79, -50.63, -51.24 ], "ebitda_estimate": [ -51, -56.5, -62 ], "net_income_estimate": [ -49.11, -49.85, -50.38 ], "per_share_eps_estimate": [ -0.45, -0.45, -0.45 ], "eps_nri_estimate": [ -0.45, -0.45, -0.45 ], "dividend_estimate": [ null, null, null ], "book_value_per_share_estimate": [ 2.3, 3.44, 2.97 ], "pretax_income_estimate": [ -50.2, -50.67, -50.96 ], "operating_cash_flow_per_share_estimate": [ -0.41, -0.42, -0.46 ], "roa_estimate": [ null, null, null ], "roe_estimate": [ null, null, null ], "gross_margin_estimate": [ 80, 80, 80 ], "operating_cash_flow_estimate": [ -44.6, -45.69, -50.04 ], "pettm_estimate": [ null, null, null ], "long_term_growth_rate_mean": 36.91, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 46.46, "future_eps_nri_estimate_growth": 36.91, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 38.64, "future_ebitda_estimate_growth": 29.66, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 37, "future_pretax_income_estimate_growth": 43.71, "future_book_value_per_share_estimate_growth": -13.42, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 14.66, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 17.04 }